Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.
Paul T NghiemShailender BhatiaEvan J LipsonWilliam H SharfmanRagini R KudchadkarAndrew S BrohlPhilip A FriedlanderAdil DaudHarriet M KlugerSunil A ReddyBrian C BoulmayAdam RikerMelissa A BurgessBrent A HanksThomas OlenckiKari KendraCandice ChurchTomoko AkaikeNirasha RamchurrenMichi M ShinoharaBob SalimJanis M TaubeErin JensenMizuho KalabisSteven P FlingBlanca Homet MorenoElad SharonMartin A CheeverSuzanne L TopalianPublished in: Journal for immunotherapy of cancer (2021)
NCT02267603.